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Proinﬂammatory diseaseIn the present study, we used solution combustion synthesis-bismuth oxide (Bi2O3) as catalyst for the
simple and efﬁcient synthesis of 1,2-oxazine based derivatives of 6-ﬂuoro-3-(piperidin-4-
yl)benzo[d]isoxazoles, 1-arylpiperazine and carbazoles. (4aR,8aR)-4-(4-Methoxyphenyl)-3-((4-(4-
methoxyphenyl)piperazin-1-yl)methyl)-4a,5,6,7,8,8a-hexahydro-4H-benzo[e][1,2]oxazine was found to
be the most potent compound with a high degree of selectivity in inhibition towards COX2 (1.7 lM) over
COX1 (40.4 lM) demonstrating the signiﬁcance of 1,2-oxazine derivatives in developing COX2 speciﬁc
inhibitors. Molecular docking analyses demonstrated that an isoleucine residue in the active site of
COX1 is responsible for lower afﬁnity to COX1 and increased potency towards COX2. Overall, our study
reveals that the new 1,2-oxazine-based small molecules qualify as lead structures in developing COX2-
speciﬁc inhibitors for anti-inﬂammatory therapy.
 2015 Elsevier Ltd. All rights reserved.Inﬂammation is a defensive response of the host immune sys-
tem against harmful antigenic invasion to minimize the deleterious
effects.1,2 Prolonged infection or delayed elimination of antigens
result in the constant triggering of the host immune system which
may lead to proinﬂammatory diseases including cancer, rheuma-
toid arthritis, atherosclerosis, inﬂammatory bowel diseases and
psoriasis.3–5 Therefore, inﬂammation can rightly be called as dou-
ble-edged sword.6 The comprehensive research in the previous dec-
ade has established the role of several proinﬂammatory mediators
in development of aforesaid diseases. The entanglement of
cyclooxygenase (COX) as one of the key proinﬂammatorymediators
has been well-demonstrated and found to be the good therapeutic
target in treating several proinﬂammatory diseases.7,8 COX1 and
COX2 are the two isoforms of cyclooxygenase in which the former
is constitutively expressed in normal tissues tomaintain homeosta-
sis and latter is renowned to express on cytokine induction in
inﬂammatory cells.9 Unfortunately, during chronic inﬂammation,COX2 is overexpressed which leads to exaggerated way of immune
response and ultimately results in developing proinﬂammatory dis-
eases.10 Copious efforts are underway to design the inhibitors
against COX2 to treat these ailments. Nonsteroidal anti-inﬂamma-
tory drugs (NSAIDs) such as Celecoxib and Rofecoxib were imple-
mented as inhibitors of COX2 in treating osteoarthritis and
rheumatoid arthritis. Recently, patients administered with
Rofecoxib were found to be prone to myocardial infarction and thus
Celecoxib is now considered a risk with regard to enhancing vascu-
lar complications.11 Given the relevance with increased adverse
effects of existing drugs, there is an immediate need for developing
the selective COX2 inhibitors with high speciﬁcity and minimal
adverse effects to treat proinﬂammatory diseases.
Oxazine, benzoxazine and isoxazoline derivatives possess wide
variety of biological activities including anti-inﬂammatory, antiox-
idants, neurosedatory and PI3 kinase inhibition.12–16 Furthermore,
diaryl heterocycles have been extensively studied as COX
inhibitors17 and many of COX inhibitors possess 1,2-diaryl substi-
tution on a four to six membered central ring system. In addition,
N-substituted phenyl piperidine, phenyl piperizine and carbazole
Figure 1. (A) Generalization of the reaction for the synthesis of oxazines. (B) Schematic representation of the title compounds using SCS-Bi2O3.
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ity. Further, carprofen is a propanoic acid conjugated carbazole
derivative and non-steroidal anti-inﬂammatory drug which selec-
tively inhibits COX2 and does not affect COX1 activity. Based on
this observation, we rationally designed and synthesized the 1,2-
oxazine derivatives and probed them against COX1 and COX2. In
continuation of our effort to synthesize and explore various phar-
macological properties of heterocycles,18–25 we herein report the
synthesis, characterization and COX2 inhibitory activity of novel
1,2-oxazine-tethered, 6-ﬂuoro-3-(piperidin-4-yl)benzo[d]isoxa-
zoles, 1-arylpiperazine and carbazoles.
Metal oxides emerged as major categories of solid catalysts in
the ﬁeld of organic synthesis. Among the metal oxide catalysts,
transition metals occupy a predominant part because of their high
activity, easy catalyst separation, long catalytic life, low cost,
reusability and selective action.26,27 In our previous study, we
reported the preparation of combustion derived Bi2O3 (SCS-Bi2O3)
and its application in cross coupling reaction28 which emphasize
not only on the basic character of Bi2O3 but also on high surface
area which makes it a promising catalyst in organic synthesis.
Initially, N-alkylation reaction was studied on piperazines,
piperidines, carbazoles using 3-bromomethyl-phenyl substituted-
4H-[1,2]oxazine derivatives.29 In the general approach, upon careful
observation it was found that using of K2CO3 as a base can cause the
decompositionof 3-bromomethyl 4-phenyl substituted1,2-oxazines.
On the other hand, usage of Na2CO3, NaHCO3, LiOH, NaOCl end up
with incomplete reaction and poor yield. In the present work, we
focused our investigation in search of the suitable base which drives
the above reactionwithout affecting theoxazinemoiety andexplored
the possibility of SCS-Bi2O3 as base catalyst towards the preparation
of new oxazines. For the selection of base-catalyst system and opti-
mization of reaction conditions, the reaction was studied on 1-(4-
methoxyphenyl)piperazine and 3-(bromomethyl)-4a,5,6,7,8,8a-hex-
ahydro-4-phenyl-4H-benzo[o][1,2]oxazines (Fig. 1A).
On N-alkylation using Bi2O3 as a base catalyst, we did not
observe the cleavage of 3-bromomethyl-4-phenyl substituted-
4H-[1,2]oxazine derivatives. However based on the experimental
results, in the presence of SCS-Bi2O3, the reaction took place effec-
tively in lesser time with better yield (Supplementary Table 1). The
most robust reaction was achieved by the use of 0.8 equiv of the
SCS-Bi2O3 acts as an effective base catalyst in 2-butanone in the
preparation of various piperazines, piperidines, and carbazoles
using 3-bromomethyl substituted oxazine derivatives (Fig. 1B).And newly synthesized novel oxazine molecules are shown in
Table 1.
More importantly, the single crystal of 3i was obtained and the
corresponding structure was identiﬁed by X-ray crystallographic
analysis (Fig. 2) supporting the formation of 1,2-oxazines via
SCS-Bi2O3 base catalysis. Signiﬁcant quality of SCS-Bi2O3 base cat-
alyst could be recovered and reused. This was investigated with a
model reaction of carbazole with 3-(bromomethyl)-4a,5,6,7,8,8a-
hexahydro-4-phenyl-4H-benzo[e][1,2]oxazine. After each run, cat-
alyst was centrifuged, washed with ethanol, dried in oven and
reused in the next run (Supplementary Fig. 1). For ﬁve catalytic
runs, we observed no considerable loss of the activity of the cata-
lyst and resulted in completion of reaction within 2 h in 88–86%
conversions against 93% of the fresh catalyst.
The crystal structure analysis showed that the compound3i crys-
tallizes in monoclinic system under the space group P21/c, with cell
parameters a = 18.2847(9) Å, b = 6.0710(4) Å, c = 20.8044(10) Å,
b = 99.789(5) and Z = 4. The bond lengths and bond angles agree
with the standard values and are comparable to a related struc-
ture.30 The heterocyclic oxazine ring adopts a half chair conforma-
tion with atoms N16 and O17 displaced by 0.754(2) and
0.317(1) Å, respectively, from the mean position. The carbazole
and benzoxazine bridged by the carbon atom, makes a dihedral
angle of 51.84(9). The methoxy phenyl group is in anti-periplanar
conformation as indicated by the torsion angle of 179.82(19). The
crystal structure (3i) is stabilized by C–H. . .N intramolecular hydro-
gen bonds, showing linear chain parallel to the c axis.
1,2-Oxazines selectively inhibits COX2 in vitro: Inﬂammation is
predominantly mediated by arachidonic acid metabolism cat-
alyzed by cyclooxygenase isoforms in various tissues.31
Considering the signiﬁcant role of COX in proinﬂammatory dis-
eases, we evaluated all the newly synthesized compounds 3a–j
for their ability to inhibit COX1 and COX2 as described previ-
ously.32 Interestingly, we found that, all the compounds displayed
high selectivity towards the inhibition of COX2 over its counterpart
indicating that 1,2-oxazines are better antagonists of COX2
(Table 2). Compounds 3a, 3b and 3c are found to be the most
potent inhibitors of COX2 with the IC50 values of 1.7, 2.6 and
1.8 lM, respectively. Nevertheless, the activity of COX1 remained
unaffected up to 35 lM.
In silico interaction studies: We attempted to retrospectively
rationalize the observed experimental afﬁnity and selectivity
proﬁle of the oxazine series by performing in silico docking
Figure 2. (A) ORTEP diagram of the molecule (3i) at 50% probability. (B) Packing of the molecule viewed parallel to the c axis. Dotted line represents the hydrogen bonds.
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whole set of compounds in both binding sites (see Fig. 3
for a representative pose prediction). The hydrophobic ligands
mostly form Van der Waals contacts with the receptor, thus
pointing towards the importance of shape complementarity
of the receptors and ligands. We observed a moderate linear
correlation of rPearson = 0.73 between docking scores and exper-
imental IC50 values over the whole data set. Each of the ele-
ven compounds in the set shows more favorable docking
scores for COX2 than for COX1 in excellent agreement with
experimental data that shows selectivities for COX2 up to fac-
tor 24. On a molecular level this can be rationalized by a sin-
gle difference in amino acid composition V523I between COX1
and COX2 binding sites that is well described in literature.33Here, the COX1 pocket bears an additional methylene group
at the Ile residue leading to a reduction in cavity size. As this
region of the binding site is consistently occupied by all pre-
dicted poses, we attribute the observed differences in binding
afﬁnities for our ligands to this steric effect that is expected
to decrease afﬁnities of bulky ligands for COX1.
In conclusion, herein we comprehensively report the synthesis
and anti-inﬂammatory potential of 1,2-oxazines mediated via
selective inhibition of COX2. Our in silico docking analysis clearly
demonstrated that presence of an auxiliary methylene group at
the isoleucine in the active site is responsible for poor interaction
of oxazines with COX1. Therefore, this report introduces 1,2-oxazi-
nes as a new class of selective COX2 inhibitors to treat various
proinﬂammatory diseases.
Table 1
Yields of the newly synthesized oxazines 3a–j
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Table 1 (continued)
Amine Bromide Product (3a–j) Mp (C) Yield (%)
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Table 2
COX1 and COX2 inhibition assay
Title compounds COX2
IC50 (lM)
COX1
IC50 (lM)
3a 1.7 40.4
3b 2.6 50.6
3c 1.8 35.8
3d 10.5 39.8
3e 4.7 42.8
3f 4.1 40.1
3g 6.8 54.9
3h 9.9 59.9
3i 5.9 50.8
3j 3.9 40.8
Indomethacin 1.2 12.5
Figure 3. Predicted binding mode of compound 3e to COX2: The protein is shown
in semi-transparent green cartoon representation with interface residues to the
docked ligand (colored by element with carbons in cyan) highlighted in thin lines
(only heavy atoms are shown respectively). COX-1/2 selectivity determining
residue V523 (shown in stick representation) is in direct contact with the oxazine
scaffold, thus directing binding preferences of the compounds.
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